ClinicalTrials.gg
Active, not recruitingNCT06257862Kujala-DKUpdated Oct 1, 2025

Translation, Cross-cultural Validity and Reliability of a Danish Version of the Anterior Knee Pain Scale

An observational study in Patella Subluxation and Patellofemoral Pain Syndrome, sponsored by Aarhus University Hospital. Active, not recruiting at 1 site in Denmark. Open to participants aged 14 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Aarhus University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
14 Years to 40 Years
Sex
All
01

Study summary

The Anterior Knee Pain Scale (Kujala) is a questionnaire designed to assess adults with patellofemoral disorders and is widely used in both anterior knee pain and patellar dislocation patients.The questionnaire is a patient-reported outcome measure (PROM), that was developed in 1993 and has been translated and validated into most major languages (e.g. French, Italian, Chinese, German, and Spanish) and has gained wide international acceptance. In a recent systematic review, the Kujala was among the eight most commonly used PROMS for patients with patellofemoral pain. In addition, the Kujala was used in almost 80% of studies of patellofemoral instability/dislocation.

The Kujala has been widely used in Denmark during the last 15 years, but surprisingly it has not been translated and validated in Danish according to international guidelines. The translation of the Kujala into Danish will stimulate to more valid and precise results of the Kujala questionnaire in both patients with anterior knee pain and patients with patellar dislocation

The aim of this study is to cross-cultural translate and adapt the Kujala into a Danish Kujala-DK. Secondarily to determine validity and reliability of the Kujala-DK in two consecutive Danish populations of patients with either anterior knee pain or patellar dislocation.

02

Conditions studied

  • Patella Subluxation
  • Patellofemoral Pain Syndrome

Keywords

  • MPFL
  • KUJALA
  • PAIN
  • Questionnaire
  • TRANSLATION
03

In context

Patellofemoral Pain Syndrome

297 studies on the registry are indexed under Patellofemoral Pain Syndrome; 73 are open to participants now.

This study's planned enrollment of 130 is above the median of 43 across 48 observational studies indexed under Patellofemoral Pain Syndrome.

Browse Patellofemoral Pain Syndrome studies →

Lead sponsor

Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MPFL-reconstructed patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Danish speaking
  • MPFL-reconstructed

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Kujala (Anterior Knee Pain Scale)

    Patient reported outcome score. (0-100 (0 = Worst, 100 = Best)

    Time frame: Baseline, after 6-8 days

  2. Victorian Institute of Sports Assessment - Patella questionnaire (VISA-P)

    Patient reported outcome score. (0-100 (0 = Worst, 100 = Best)

    Time frame: Baseline

  3. International knee documentation committee (IKDC)

    Patient reported outcome score. (0-100 (0 = Worst, 100 = Best)

    Time frame: Baseline

  4. Banff patella instability instrument (BPII 2.0)

    Patient reported outcome score. (0-100 (0 = Worst, 100 = Best)

    Time frame: Baseline

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06257862
Responsible party
Martin Lind (Professor, PhD, MD, Aarhus University Hospital) — Principal investigator
First posted
Feb 14, 2024
Start date
Mar 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion